Unknown

Dataset Information

0

Cell motility and drug gradients in the emergence of resistance to chemotherapy.


ABSTRACT: The emergence of resistance to chemotherapy by cancer cells, when combined with metastasis, is the primary driver of mortality in cancer and has proven to be refractory to many efforts. Theory and computer modeling suggest that the rate of emergence of resistance is driven by the strong selective pressure of mutagenic chemotherapy and enhanced by the motility of mutant cells in a chemotherapy gradient to areas of higher drug concentration and lower population competition. To test these models, we constructed a synthetic microecology which superposed a mutagenic doxorubicin gradient across a population of motile, metastatic breast cancer cells (MDA-MB-231). We observed the emergence of MDA-MB-231 cancer cells capable of proliferation at 200 nM doxorubicin in this complex microecology. Individual cell tracking showed both movement of the MDA-MB-231 cancer cells toward higher drug concentrations and proliferation of the cells at the highest doxorubicin concentrations within 72 h, showing the importance of both motility and drug gradients in the emergence of resistance.

SUBMITTER: Wu A 

PROVIDER: S-EPMC3791735 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cell motility and drug gradients in the emergence of resistance to chemotherapy.

Wu Amy A   Loutherback Kevin K   Lambert Guillaume G   Estévez-Salmerón Luis L   Tlsty Thea D TD   Austin Robert H RH   Sturm James C JC  

Proceedings of the National Academy of Sciences of the United States of America 20130917 40


The emergence of resistance to chemotherapy by cancer cells, when combined with metastasis, is the primary driver of mortality in cancer and has proven to be refractory to many efforts. Theory and computer modeling suggest that the rate of emergence of resistance is driven by the strong selective pressure of mutagenic chemotherapy and enhanced by the motility of mutant cells in a chemotherapy gradient to areas of higher drug concentration and lower population competition. To test these models, w  ...[more]

Similar Datasets

| S-EPMC7338613 | biostudies-literature
| S-EPMC10517696 | biostudies-literature
| S-EPMC4547268 | biostudies-literature
| S-EPMC6874398 | biostudies-literature
| S-EPMC7163045 | biostudies-literature
| S-EPMC1172248 | biostudies-literature
| S-EPMC7197350 | biostudies-literature
| S-EPMC4747401 | biostudies-literature
| S-EPMC4481510 | biostudies-literature
| S-EPMC6510230 | biostudies-literature